top of page

Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously

Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and the targets the company is currently working on.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page